Genetic technique may open new doors to fighting dengue fever | PRP therapy relieves elbow pain better than other care in study | Calif. institute grants $26M for stem cell research
Web Version
 
 
March 22, 2013
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP|FORWARD|ARCHIVE

Top Story
Genetic technique may open new doors to fighting dengue fever
Scientists at Virginia Tech have developed a method for deleting genes in the mosquito that spreads the dengue virus. The technology involves two engineered proteins in a class called transcription activator-like effector nucleases. Previous consideration of genetic dengue controls involved the addition of genes. "This technology allows us to pursue the same goals, namely, the generation of pathogen-resistant mosquitoes, through subtraction," an entomologist said. NBC News/Cosmic Log blog (3/21)
Share: LinkedInTwitterFacebookGoogle+Email
Clinical Research: Understanding the Methodology Toolbox
Clinical Research: Understanding the Methodology Toolbox compiles articles of evidence-based research for use as an educational resource for those involved in clinical research, healthcare professionals and trainees in transfusion medicine and other medical specialties. Now in the AABB Marketplace.
Advertisement
 
Science & Health
PRP therapy relieves elbow pain better than other care in study
Platelet-rich plasma therapy may relieve pain associated with chronic tennis elbow up to six months following the treatment, according to a study of 230 patients reported at an orthopedic surgeons' meeting. Twelve weeks after treatment, patients who received the treatment reported 55% improvement in pain scores, compared with about 47% for patients who received standard treatment. At six months, platelet treatment was associated with 72% improvement in pain scores, compared with about 56% in the comparison group. DailyRx.com (3/21)
Share: LinkedInTwitterFacebookGoogle+Email
Calif. institute grants $26M for stem cell research
The California Institute for Regenerative Medicine awarded Cellular Dynamics International $16 million to develop three induced pluripotent stem cell lines for each of 3,000 samples from ill and healthy donors. The institute also will give $10 million to the Coriell Institute for Medical Research to create a biobank for the cell lines and a repository for the samples. American City Business Journals/Philadelphia (3/21)
Share: LinkedInTwitterFacebookGoogle+Email
Emerging Trends
Budget cut could jeopardize poor's access to HIV/AIDS drugs
The House and the Senate so far have failed to earmark $35 million in funding for state AIDS Drug Assistance Programs, which endangers their capacity to provide access to treatments for almost 8,000 patients with HIV, advocates said. Some states, including Florida and Illinois, may have to stop giving drugs, AIDS Institute Deputy Executive Director Carl Schmid said. Pharmalot/Pharma Blog (3/20)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
EU approves bleeding control device from iTraumaCar
Canadian firm iTraumaCar has received European approval for its iTClamp Hemorrhage Control System, which was developed by a retired Canadian military surgeon to address severe bleeding from open wounds, particularly when drugs and tourniquets are not adequate. The system could be used by civilian first responders and on the battlefield. MedGadget.com (3/21)
Share: LinkedInTwitterFacebookGoogle+Email
Mass. blood collection device firm obtains $1.9M
Seventh Sense Biosystems has obtained $1.9 million in a round of debt funding from five unnamed investors. Last summer, the Cambridge, Mass.-based startup also raised $10 million in a Series A round that it said would finance the development and commercialization of its Touch Activated Phlebotomy device, its first blood collection product. American City Business Journals/Boston/BioFlash blog (3/21)
Share: LinkedInTwitterFacebookGoogle+Email
Dendritic cell production patent is awarded to NW Bio
Northwest Biotherapeutics obtained a U.S. patent for technology involving the production of human dendritic cells. The method mirrors the way the immune system produces the cells, the firm said. Pharmaceutical Business Review Online (3/20)
Share: LinkedInTwitterFacebookGoogle+Email
Fatigue contributes to provider errors, survey suggests
Data from the Nurse Staffing Strategy survey revealed 27% of providers reported committing fatigue-related errors, and nearly 65% said they almost committed errors because of fatigue. Sixty-nine percent said they felt concerned about performing well during work hours due to exhaustion. BeckersHospitalReview.com (3/20)
Share: LinkedInTwitterFacebookGoogle+Email
Government & Regulatory
Rivaroxaban gets EU support for use with acute coronary syndrome
The anticoagulant rivaroxaban should be considered for preventive use in patients with acute coronary syndrome, according to a recommendation from the EU's Committee for Medicinal Products for Human Use. The panel's opinion comes weeks after the FDA sought additional information instead of approving a similar indication in the U.S. TheHeart.org (Montreal) (free registration) (3/22), Bloomberg Businessweek (3/22)
Share: LinkedInTwitterFacebookGoogle+Email
States take action on compounding pharmacies
State scrutiny of specialty pharmacies is increasing in response to last fall's deadly meningitis outbreak tied to tainted steroids from the New England Compounding Center. States are considering making pharmacies get special permits to mix sterile drugs, and surprise inspections are being conducted. Virginia and Maryland are among a dozen states considering tighter licensing requirements. New York regulators issued a sales moratorium for one of the nation's biggest compounders, while Iowa's pharmacy board hopes to inspect more than 600 out-of-state compounders that supply medicines to the state. The Washington Post (tiered subscription model) (3/20)
Share: LinkedInTwitterFacebookGoogle+Email
CMS announces MU targets for hospitals, physician practices for 2013
CMS said at the HIMSS13 conference that it anticipates 80% of qualified hospitals and 50% of qualified physician practices will become meaningful users this year. Acting CMS Administrator Marilyn Tavenner said 2013 would be "busy," with a focus on education. "We're going to spend a lot more time with physicians -- helping physicians learn, and helping physicians work with their current vendors to make things a little easier for them," Tavenner said. Family Practice News (3/19)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
RBC Transfusion Data Card now available in AABB Marketplace
The RBC Transfusion Data Card is available for purchase in the AABB Marketplace. The data card is a pocket-sized reference guide that summarizes red blood cell transfusion guidelines for treating adults and pediatric patients. Indications, contraindications and key points on administration are included on the card.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Associate Medical DirectorBloodCenter of WisconsinUS - WI - Milwaukee
Director, Quality (CTS-Chicago)Blood Systems, Inc.US - IL - Rosemont
Director, Community Center IIUnited Blood ServicesUS - SD - Rapid City
Quality SpecialistBlood Systems, Inc.US - AZ - Scottsdale
Quality Specialist (BCP)Blood Systems, Inc.US - CA - San Francisco
Laboratory SupervisorBaxter HealthcareUS - AL - Hoover
Click here to view more job listings.
 
SmartQuote
If we were all given by magic the power to read each other's thoughts, I suppose the first effect would be to dissolve all friendships."
-- Bertrand Russell,
British philosopher, mathematician and historian
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising Manager:  Annette Bacchus
  M: 240.333.6604
Jobs Contact:  Jackie Basso
  P: 202.407.7871
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information